Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it not for looming cost hikes from the recent tariff war.

Abbott Laboratories will make new investments in US manufacturing, with the impact of tariffs on medical devices and diagnostics looming over the industry.

Abbott Lab’s stock bucks a broad market selloff, after quarterly profit extends a long streak of beats on the back of strong demand for diabetes products.